BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 18185913)

  • 1. Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen.
    Schindlbeck C; Stellwagen J; Jeschke U; Karsten U; Rack B; Janni W; Jückstock J; Tulusan A; Sommer H; Friese K
    Clin Exp Metastasis; 2008; 25(3):233-40. PubMed ID: 18185913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.
    Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Sommer H; Friese K
    Histochem Cell Biol; 2005 Jun; 123(6):631-7. PubMed ID: 15889266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of Thomsen-Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients.
    Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Krajewski S; Sommer H; Friese K
    Breast Cancer Res Treat; 2007 Jan; 101(1):17-25. PubMed ID: 16807671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood.
    Naume B; Borgen E; Beiske K; Herstad TK; Ravnås G; Renolen A; Trachsel S; Thrane-Steen K; Funderud S; Kvalheim G
    J Hematother; 1997 Apr; 6(2):103-14. PubMed ID: 9131439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and characterisation of disseminated tumour cells in bone marrow of breast cancer patients by immunostaining of Her-2 and MUC-1 in combination with Thomsen-Friedenreich (CD176).
    Andergassen U; Kölbl AC; Zebisch M; Heublein S; Hutter S; Ilmer M; Schindlbeck C; Friese K; Jeschke U
    Histol Histopathol; 2014 Jul; 29(7):913-23. PubMed ID: 24399516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
    Fehm T; Hoffmann O; Aktas B; Becker S; Solomayer EF; Wallwiener D; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(4):R59. PubMed ID: 19664291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
    Kasimir-Bauer S; Reiter K; Aktas B; Bittner AK; Weber S; Keller T; Kimmig R; Hoffmann O
    Sci Rep; 2016 May; 6():26355. PubMed ID: 27212060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method.
    Naume B; Borgen E; Tøssvik S; Pavlak N; Oates D; Nesland JM
    Cytotherapy; 2004; 6(3):244-52. PubMed ID: 15203981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment.
    Stefanovic S; Diel I; Sinn P; Englert S; Hennigs A; Mayer C; Schott S; Wallwiener M; Blumenstein M; Golatta M; Heil J; Rom J; Sohn C; Schneeweiss A; Schuetz F; Domschke C
    Ann Surg Oncol; 2016 Mar; 23(3):757-66. PubMed ID: 26467455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity.
    Gröbe A; Blessmann M; Hanken H; Friedrich RE; Schön G; Wikner J; Effenberger KE; Kluwe L; Heiland M; Pantel K; Riethdorf S
    Clin Cancer Res; 2014 Jan; 20(2):425-33. PubMed ID: 24218516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer.
    Hartkopf AD; Stefanescu D; Wallwiener M; Hahn M; Becker S; Solomayer EF; Fehm TN; Brucker SY; Taran FA
    Breast Cancer Res Treat; 2014 Sep; 147(2):345-51. PubMed ID: 25151295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
    Hoffmann O; Aktas B; Goldnau C; Heubner M; Oberhoff C; Kimmig R; Kasimir-Bauer S
    Anticancer Res; 2011 Oct; 31(10):3623-8. PubMed ID: 21965788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients.
    Woelfle U; Breit E; Zafrakas K; Otte M; Schubert F; Müller V; Izbicki JR; Löning T; Pantel K
    J Immunol Methods; 2005 May; 300(1-2):136-45. PubMed ID: 15907331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
    Wimberger P; Heubner M; Otterbach F; Fehm T; Kimmig R; Kasimir-Bauer S
    Gynecol Oncol; 2007 Nov; 107(2):331-8. PubMed ID: 17764727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
    Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
    Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
    Magbanua MJM; Yau C; Wolf DM; Lee JS; Chattopadhyay A; Scott JH; Bowlby-Yoder E; Hwang ES; Alvarado M; Ewing CA; Delson AL; Van't Veer LJ; Esserman L; Park JW
    Clin Cancer Res; 2019 Sep; 25(17):5388-5397. PubMed ID: 31142502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer.
    Wiedswang G; Borgen E; Schirmer C; Kåresen R; Kvalheim G; Nesland JM; Naume B
    Int J Cancer; 2006 Apr; 118(8):2013-9. PubMed ID: 16287086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients.
    Schindlbeck C; Andergassen U; Hofmann S; Jückstock J; Jeschke U; Sommer H; Friese K; Janni W; Rack B
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):1055-62. PubMed ID: 23525580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization.
    Riethdorf S; Pantel K
    Pathobiology; 2008; 75(2):140-8. PubMed ID: 18544969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.